Given the difficulty of clearing a path to market for generics and biosimilars, Arrow declarations can serve as a valuable defensive litigation tool in the United Kingdom when patent invalidation or non-infringement judgments are difficult to obtain.  Please see full article by Peter Damerell and William Hillson here.

This article first appeared in IAM Issue 94, published by Globe Business Media Group - IP Division. To view the issue in full, please go to www.IAM-media.com